Day: September 22, 2021

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — Marble Financial Inc. (CSE: MRBL; OTC: MRBLF; FSE:2V0) (“Marble” or the “Company”), an AI-driven financial technology company that educates and helps Canadians better understand and manage their current cash flow and credit towards a better financial future, is pleased to announce that its subsidiary, Inverite Verification Inc. (“Inverite”), has reported record growth and transaction volume milestones. Inverite Verification Inc. (“Inverite”), a leading Canadian open banking and consumer-directed finance data provider offering innovative, secure and cost-effective banking verification solutions to the financial services industry is proud to announce that in August 2021 it has surpassed 80,000 monthly transactions and recorded an increase of 42% YoY in its unique end-user...

Meeting Scheduled for October 14, 2021 Stockholders of Record as of August 18, 2021 are Eligible to Vote at Special Meeting NEW YORK, NY, Sept. 22, 2021 (GLOBE NEWSWIRE) — Legato Merger Corp. (“Legato”) (Nasdaq: LEGOU, LEGO, LEGOW), a publicly traded special purpose acquisition company, today announced that its Special Meeting of Stockholders (the “Special Meeting”) has been set for October 14, 2021 at 11:00 a.m.EST. Stockholders of record as of August 18, 2021 (the “Record Date”) are eligible to vote at the Special Meeting to consider the previously announced business combination with Algoma Steel Group Inc. (“Algoma” or the “Company”), a fully integrated producer of hot and cold rolled steel products including sheet and plate.. About Algoma Steel Based in Sault Ste. Marie, Ontario, Canada, Algoma is a fully integrated producer...

NOT FOR DISSEMINATION, DISTRIBUTION, RELEASE, OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — Candelaria Mining Corp. (TSX-V: CAND, OTC PINK: CDELF) (the “Company”) is pleased to announce that, further to its press release of September 1, 2021, and due to investor demand, it has upsized its non-brokered private placement from gross proceeds of $7,800,000 to up to $9,300,000 through the issuance of up to 20,666,666 units of the Company (the “Units”) at a price of $0.45 per Unit (the “Offering”). Each Unit will consist of one common share of the Company and one-half of a common share purchase warrant (the “Warrants”), with each full Warrant entitling the holder thereof to acquire one common share of the...

Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2 HAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the Food and Drug Administration (FDA) for the company’s DPP Respiratory Antigen Panel test system. The DPP Respiratory Antigen Panel test system is designed to provide simultaneous, discrete, and differential detection of Influenza A, Influenza B, and SARS-CoV-2 antigens from a single patient sample using a simple nasal swab. The test system is expected to provide results in approximately 20 minutes and be read on Chembio’s DPP Micro Reader analyzer. The system is intended to enable appropriate clinical management...

TORONTO, Sept. 22, 2021 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), announces completion of the initial stage of the Company’s 2021 heap leach metallurgical test work program for the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA. The work is being performed by SGS Lakefield (“SGS”) under the direction of metallurgical staff from Revival Gold’s engineering consultant, Wood. Sample material, consisting of 1.94 tonnes of material from Beartrack and 0.80 tonnes of material from Arnett, was delivered to SGS in June 2021. The first stage of the test work program included head analysis, acid base accounting and bottle roll tests. The second stage of the program consists of column tests and will commence this month. The primary goal of the test work program...

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (U.S. FDA) for its investigation of NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC).  This initiates formal communications with the U.S. FDA regarding development of the Company’s newly announced SCLC clinical research program and related license agreement with Dartmouth College. In the pre-IND meeting request application, the Company is confirming the direction it plans to take in the development of Ifenprodil as an adjunct to Topotecan for the treatment of...